IMID BioResource

• Research type

  Research Study

• Full title

  IMID (Immune-Mediated Inflammatory Diseases)BioResource - part of NIHR BioResource

• IRAS ID

  263004

• Contact name

  Ian Bruce

• Contact email

  ian.bruce@manchester.ac.uk

• Sponsor organisation

  Manchester University NHS Foundation Trust

• Duration of Study in the UK

  2 years, 4 months, 31 days

• Research summary

  Working with the NIHRBR, we are proposing to develop a centralised national recallable bioresource of 24,000 patients and relatives of patients with one or more of a spectrum of disorders which comprise immune-mediated inflammatory diseases (IMIDs), to support scientific and clinical IMID research.
  1. DNA and serum + clinical and genetic data from 24,000 IMID patients and relatives recruited England-wide stored in a central biorepository funded by NIHR BioResource
  2. Stratify participants into core datasets for analysis
  3. Recallability - run by NIHRBR National Co-ordinating Centre, allowing patients stratified by clinical subtype or comorbidities to be recruited for future scientific or clinical trials (with additional approvals and consent)
  Immune-mediated inflammatory diseases (IMIDs) are a spectrum of disorders with shared susceptibility genes, overlapping ways in which the immune response is developed, clinical features and comorbidities. However each disease also has unique disease-specific pathways in which they develop. Some treatments are effective against all these diseases, however others are not and can paradoxically make the condition worse. Learning about how these mechanisms work will help to target effective therapies to each specific disease area.

  IMID BioResource will focus on 3 pivotal IMIDs and 3 cross-cutting co-morbidities:
  • Rheumatoid Arthritis (RA)
  • Psoriasis (and the linked seronegative spondyloarthropathies family)
  • SLE and related syndromes: mixed and undifferentiated connective tissue diseases (MCTD and UCTD)
  Cross-cutting co-morbidity phenotypes will initially focus on
  • Chronic lung disease including COPD and Interstitial lung disease (ILD)
  • Cardiovascular disease (CVD)
  • Fatigue/mood disorders

  The NIHRBR-IMID will be managed by a partnership across the 3 Northern Biomedical Research Centres (BRCs) (Manchester, Newcastle and Leeds) and co-ordinated from Manchester BRC. NIHRBR-IMID reflects common and overlapping areas in which all three partners demonstrate (inter)national leadership and expertise. Strategically NIHRBR-IMID will complement and synergise with existing BioResource supported diseases including a number of Rare Diseases.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  19/NW/0760

• Date of REC Opinion

  16 Jan 2020

• REC opinion

  Further Information Favourable Opinion